uniQure N.V. (QURE) Bundle
An Overview of uniQure N.V. (QURE)
General Summary of uniQure N.V. (QURE)
uniQure N.V. is a Netherlands-based gene therapy company founded in 2012. The company specializes in developing innovative treatments for genetic disorders.
| Company Detail | Specific Information |
|---|---|
| Headquarters | Amsterdam, Netherlands |
| Founded | 2012 |
| Stock Exchange | NASDAQ |
Key Product Portfolio
- Hemophilia B gene therapy (Hemgenix)
- Huntington's disease treatment programs
- Cardiovascular gene therapy solutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $64.3 million |
| Net Loss | $136.7 million |
| Cash and Investments | $377.1 million |
Industry Leadership
uniQure N.V. is recognized as a pioneering gene therapy company with multiple clinical-stage programs targeting rare genetic disorders.
| Clinical Development Stage | Number of Programs |
|---|---|
| Phase 1/2 | 3 programs |
| Phase 3 | 1 program |
Mission Statement of uniQure N.V. (QURE)
Mission Statement of uniQure N.V. (QURE)
uniQure N.V. focuses on developing gene therapies to address rare and devastating diseases.
Core Mission Components
| Component | Specific Focus | 2024 Metrics |
|---|---|---|
| Gene Therapy Innovation | Rare Neurological Disorders | 3 clinical-stage programs |
| Research Investment | Advanced Therapeutic Platforms | $127.4 million R&D expenditure (2023) |
| Patient-Centric Approach | Precision Medicine Development | 2 FDA breakthrough therapy designations |
Strategic Research Focus
- Hemophilia B gene therapy
- Huntington's disease treatment
- Parkinson's disease gene therapy
Research Pipeline Metrics
| Program | Development Stage | Current Status |
|---|---|---|
| AMT-130 | Phase II Clinical Trial | Huntington's Disease |
| AMT-060 | Phase III Development | Hemophilia B |
Financial Investment in Research
2023 total research and development expenses: $127.4 million
Cash and cash equivalents as of December 31, 2023: $391.8 million
Vision Statement of uniQure N.V. (QURE)
Vision Statement Components of uniQure N.V. (QURE) in 2024
Gene Therapy Innovation LeadershipuniQure N.V. focuses on developing breakthrough gene therapies targeting rare genetic diseases. As of Q4 2023, the company's pipeline includes 6 active clinical-stage programs across multiple therapeutic areas.
| Therapeutic Area | Clinical Stage Programs | Target Indication |
|---|---|---|
| Hemophysis | 2 | Hemophilia B |
| Neurological Disorders | 3 | Huntington's Disease |
| Cardiovascular | 1 | Congestive Heart Failure |
uniQure aims to develop transformative gene therapies with potential global reach. Current research investment stands at $127.3 million for 2024.
- Research & Development Budget: $127.3 million
- Active Clinical Trials: 9
- Geographic Research Expansion: North America, Europe
The company's precision medicine strategy targets specific genetic mutations with personalized therapeutic solutions.
| Technology Platform | Genetic Targeting Capability | Precision Metrics |
|---|---|---|
| AAV Gene Delivery | 95% Genetic Specificity | Targeted Mutation Correction |
Core Values of uniQure N.V. (QURE)
Core Values of uniQure N.V. (QURE) in 2024
Innovation and Scientific Excellence
uniQure N.V. demonstrates commitment to innovation through significant research investments.
| R&D Metric | 2024 Value |
|---|---|
| R&D Expenditure | $184.2 million |
| Active Gene Therapy Programs | 7 distinct programs |
| Patent Portfolio | 52 granted patents |
Patient-Centric Approach
- Rare genetic disease focus
- Hemophysis B clinical trials active patients: 48
- Huntington's Disease program: 3 ongoing clinical trials
Ethical Commitment
| Ethical Compliance Metric | 2024 Status |
|---|---|
| Clinical Trial Transparency Rating | 94% compliance |
| Regulatory Audit Outcomes | Zero critical findings |
Collaborative Research Approach
Partnerships and collaborations in 2024:
- Academic Partnerships: 6 active research collaborations
- Pharmaceutical Collaboration Agreements: 3 strategic partnerships
- Total Collaborative Research Budget: $42.7 million
Sustainable Development
| Sustainability Metric | 2024 Value |
|---|---|
| Carbon Emission Reduction | 23% reduction from 2023 baseline |
| Renewable Energy Usage | 47% of total energy consumption |
uniQure N.V. (QURE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.